1. Home
  2. AYTU vs DLPN Comparison

AYTU vs DLPN Comparison

Compare AYTU & DLPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • DLPN
  • Stock Information
  • Founded
  • AYTU N/A
  • DLPN N/A
  • Country
  • AYTU United States
  • DLPN United States
  • Employees
  • AYTU N/A
  • DLPN N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • DLPN Other Consumer Services
  • Sector
  • AYTU Health Care
  • DLPN Consumer Discretionary
  • Exchange
  • AYTU Nasdaq
  • DLPN Nasdaq
  • Market Cap
  • AYTU 8.3M
  • DLPN 11.6M
  • IPO Year
  • AYTU N/A
  • DLPN N/A
  • Fundamental
  • Price
  • AYTU $1.26
  • DLPN $1.01
  • Analyst Decision
  • AYTU
  • DLPN Strong Buy
  • Analyst Count
  • AYTU 0
  • DLPN 1
  • Target Price
  • AYTU N/A
  • DLPN $5.00
  • AVG Volume (30 Days)
  • AYTU 46.7K
  • DLPN 21.6K
  • Earning Date
  • AYTU 02-12-2025
  • DLPN 03-27-2025
  • Dividend Yield
  • AYTU N/A
  • DLPN N/A
  • EPS Growth
  • AYTU N/A
  • DLPN N/A
  • EPS
  • AYTU N/A
  • DLPN N/A
  • Revenue
  • AYTU $77,232,000.00
  • DLPN $51,389,626.00
  • Revenue This Year
  • AYTU N/A
  • DLPN $21.74
  • Revenue Next Year
  • AYTU $8.14
  • DLPN $7.26
  • P/E Ratio
  • AYTU N/A
  • DLPN N/A
  • Revenue Growth
  • AYTU N/A
  • DLPN 21.66
  • 52 Week Low
  • AYTU $1.23
  • DLPN $0.90
  • 52 Week High
  • AYTU $3.45
  • DLPN $3.04
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 32.98
  • DLPN 45.98
  • Support Level
  • AYTU $1.24
  • DLPN $1.02
  • Resistance Level
  • AYTU $1.32
  • DLPN $1.14
  • Average True Range (ATR)
  • AYTU 0.07
  • DLPN 0.07
  • MACD
  • AYTU 0.00
  • DLPN -0.01
  • Stochastic Oscillator
  • AYTU 13.64
  • DLPN 16.76

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

Share on Social Networks: